Cue Biopharma Inc (NAS:CUE)

$ 1.35 0.01 (0.75%) Market Cap: 65.67 Mil Enterprise Value: 37.63 Mil PE Ratio: 0 PB Ratio: 2.18 GF Score: 50/100

Q4 2023 Cue Biopharma Inc Earnings Call Transcript
Apr 08, 2024

$2.04 (+10.27%)

Earnings
Q3 2023 Cue Biopharma Inc Earnings Call and Business Update Transcript
Nov 09, 2023

$2.08 (-11.32%)

Earnings
Q2 2023 Cue Biopharma Inc Earnings Call Transcript
Aug 09, 2023

$3.62 (+1.12%)

Earnings
Cue Biopharma Inc To Host Business Update Call Transcript
Jun 14, 2023
Cue Biopharma Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Cue Biopharma Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Q4 2022 Cue Biopharma Inc Earnings Call Transcript
Mar 21, 2023

$3.38 (+9.39%)

Earnings
Q3 2022 Cue Biopharma Inc Earnings Call Transcript
Nov 14, 2022

$3.25 (+3.50%)

Earnings
Q2 2022 Cue Biopharma Inc Earnings And Business Update Call Transcript
Aug 23, 2022
Cue Biopharma Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022
Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call Transcript
Jan 26, 2022
Q2 2021 Cue Biopharma Inc Earnings Call Transcript
Aug 17, 2021

$10.32 (+1.57%)

Earnings
Q1 2021 Cue Biopharma Inc Earnings Call Transcript
May 17, 2021

$14 (+2.41%)

Earnings
Q4 2020 Cue Biopharma Inc Earnings Call Transcript
Mar 16, 2021

$14.82 (-1.92%)

Earnings
Cue Biopharma Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Cue Biopharma, Inc. - Special Call Transcript
Nov 17, 2020
Cue Biopharma Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Cue Biopharma Inc Earnings Call Transcript
Aug 31, 2020

$17.87 (+0.79%)

Earnings
Q1 2020 Cue Biopharma Inc Earnings Call Transcript
May 19, 2020

$27.14 (+2.18%)

Earnings
Q4 2019 Cue Biopharma Inc Earnings Call Transcript
Mar 17, 2020

$11.41 (-2.14%)

Earnings
Cue Biopharma, Inc. - Special Call Transcript
Nov 12, 2019
Cue Biopharma Inc Investor Business Update Transcript
May 21, 2019
Cue Biopharma, Inc. - Special Call Transcript
Mar 14, 2019

Cue Biopharma Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 09:00PM GMT

Release Date Price: $17.21 (-2.22%)

Transcript

Albert Hwang;Morgan Stanley;Managing Director

Head of Biotechnology Investment Banking,

Good afternoon, everybody. Thank you for coming today for the Morgan Stanley Healthcare Conference. Today, this afternoon, I have with me Dan Passeri, the CEO of Cue. And why don't I pass it off to Dan to introduce the rest of the management team? The format here will be a 10-minute overview of the company followed by a Q&A led by me. (Operator Instructions) Dan?

Daniel R. Passeri

Cue Biopharma, Inc. - CEO & Director

Okay. Thanks, Albert. Good afternoon, everyone. I'm joined here by -- with my colleague, Anish Suri, who's President and Chief Scientific Officer of Cue Biopharma.

Just to remind everyone, Cue is a NASDAQ-listed company. Symbol is CUE. I also want to thank Morgan Stanley for giving us an opportunity to present.

I'm going to be advancing slides here at our facility, and I'll tell you which slides we're on. You can advance them off of your computers directly.

We're now moving to Slide 2.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.